Christine Brezden-Masley1, Kelly E Fathers2, Megan E Coombes3, Behin Pourmirza2, Cloris Xue2, Katarzyna J Jerzak4. 1. Division of Medical Oncology and Hematology, Faculty of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada. 2. Department of Medical Affairs, Hoffmann-La Roche Limited, Mississauga, ON, Canada. 3. Market Access and Pricing Department, Hoffmann-La Roche Limited, Mississauga, ON, Canada. 4. Division of Medical Oncology and Hematology, Faculty of Medicine, Sunnybrook Odette Cancer Center, University of Toronto, Toronto, ON, Canada. katarzyna.jerzak@sunnybrook.ca.
Abstract
PURPOSE: To update and expand on data related to treatment, resource utilization, and costs by cancer stage in Canadian patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC). METHODS: We analyzed data for adult women diagnosed with invasive HR+/HER2- BC between 2012 and 2016 utilizing the publicly funded health care system in Ontario. Baseline characteristics, treatment received, and health care use were descriptively compared by cancer stage (I-III vs. IV). Resource use was multiplied by unit costs for publicly funded health care services to calculate costs. RESULTS: Our study included 21,360 patients with stage I-III plus 813 with stage IV HR+/HER2- BC. Surgery was performed on 20,510 patients with stage I-III disease (96.0%), with the majority having a lumpectomy, and radiation was received by 15,934 (74.6%). Few (n = 1601, 7.8%) received neoadjuvant and most (n = 15,655, 76.3%) received adjuvant systemic treatment. Seven hundred and fifty eight patients with metastatic disease (93.2%) received systemic therapy; 542 (66.7%) received endocrine therapy. Annual per patient health care costs were three times higher in the stage IV vs. stage I-III cohort with inpatient hospital services representing nearly 40% of total costs. CONCLUSION: The costs associated with metastatic HR+/HER2- BC reflect a significant disease burden. Low endocrine treatment rates captured by the publicly funded system suggest guideline non-adherence or that a fair portion of Ontarian patients may be incurring out-of-pocket drug costs.
PURPOSE: To update and expand on data related to treatment, resource utilization, and costs by cancer stage in Canadian patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC). METHODS: We analyzed data for adult women diagnosed with invasive HR+/HER2- BC between 2012 and 2016 utilizing the publicly funded health care system in Ontario. Baseline characteristics, treatment received, and health care use were descriptively compared by cancer stage (I-III vs. IV). Resource use was multiplied by unit costs for publicly funded health care services to calculate costs. RESULTS: Our study included 21,360 patients with stage I-III plus 813 with stage IV HR+/HER2- BC. Surgery was performed on 20,510 patients with stage I-III disease (96.0%), with the majority having a lumpectomy, and radiation was received by 15,934 (74.6%). Few (n = 1601, 7.8%) received neoadjuvant and most (n = 15,655, 76.3%) received adjuvant systemic treatment. Seven hundred and fifty eight patients with metastatic disease (93.2%) received systemic therapy; 542 (66.7%) received endocrine therapy. Annual per patient health care costs were three times higher in the stage IV vs. stage I-III cohort with inpatient hospital services representing nearly 40% of total costs. CONCLUSION: The costs associated with metastatic HR+/HER2- BC reflect a significant disease burden. Low endocrine treatment rates captured by the publicly funded system suggest guideline non-adherence or that a fair portion of Ontarian patients may be incurring out-of-pocket drug costs.
Entities:
Keywords:
Breast neoplasms; Cohort studies; Drug therapy; Health services research; Radiotherapy; Receptors steroid; Surgical procedures operative
Authors: Harold J Burstein; Ann Alexis Prestrud; Jerome Seidenfeld; Holly Anderson; Thomas A Buchholz; Nancy E Davidson; Karen E Gelmon; Sharon H Giordano; Clifford A Hudis; Jennifer Malin; Eleftherios P Mamounas; Diana Rowden; Alexander J Solky; Maryfran R Sowers; Vered Stearns; Eric P Winer; Mark R Somerfield; Jennifer J Griggs Journal: J Clin Oncol Date: 2010-07-12 Impact factor: 44.544
Authors: Stephanie Brooke Wheeler; Racquel Elizabeth Kohler; Katherine Elizabeth Reeder-Hayes; Ravi K Goyal; Kristen Hassmiller Lich; Alexis Moore; Timothy W Smith; Cathy L Melvin; Hyman Bernard Muss Journal: J Cancer Surviv Date: 2014-05-28 Impact factor: 4.442
Authors: Carlo Messina; Carlo Cattrini; Giulia Buzzatti; Luigi Cerbone; Elisa Zanardi; Marco Messina; Francesco Boccardo Journal: Breast Cancer Res Treat Date: 2018-07-27 Impact factor: 4.872
Authors: Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes Journal: J Clin Oncol Date: 2006-12-11 Impact factor: 44.544
Authors: Jame Abraham; Robert Coleman; Anthony Elias; Frankie Ann Holmes; Kevin Kalinsky; Muaiad Kittaneh; Elyse Lower; Reshma Mahtani; E Terry Mamounas; Mark Pegram; Charles Vogel Journal: Breast Cancer Res Treat Date: 2018-05-04 Impact factor: 4.872
Authors: Joseph A Sparano; Molin Wang; Fengmin Zhao; Vered Stearns; Silvana Martino; Jennifer A Ligibel; Edith A Perez; Tom Saphner; Antonio C Wolff; George W Sledge; William C Wood; John Fetting; Nancy E Davidson Journal: Cancer Date: 2012-08-27 Impact factor: 6.860
Authors: Anna N Wilkinson; Jean-Michel Billette; Larry F Ellison; Michael A Killip; Nayaar Islam; Jean M Seely Journal: Curr Oncol Date: 2022-08-09 Impact factor: 3.109